Setmelanotide + Placebo

Phase 3Recruiting

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Hypothalamic Obesity

Conditions

Hypothalamic Obesity, Multiple Pituitary Hormone Deficiency Genetic Form, Septo-Optic Dysplasia, Optic Nerve Hypoplasia, Childhood-onset Combined Pituitary Hormone Deficiency, Pituitary Stalk Interruption Syndrome

Trial Timeline

Sep 23, 2025 → Mar 13, 2028

NCT ID

NCT06760546

About Setmelanotide + Placebo

Setmelanotide + Placebo is a phase 3 stage product being developed by Rhythm Pharmaceuticals for Hypothalamic Obesity. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06760546. Target conditions include Hypothalamic Obesity, Multiple Pituitary Hormone Deficiency Genetic Form, Septo-Optic Dysplasia.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (10)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06760546	Phase 3	Recruiting	Sep 23, 2025	Mar 13, 2028	Hypothalamic Obesity
NCT05774756	Phase 3	Active	Apr 26, 2023	Apr 16, 2027	Hypothalamic Obesity
NCT05093634	Phase 3	Active	Dec 10, 2021	Dec 31, 2026	Obesity
NCT04963231	Phase 2	Completed	Nov 30, 2021	Sep 30, 2024	Genetic Obesity
NCT03746522	Phase 3	Completed	Nov 23, 2018	Mar 8, 2021	Bardet Biedl Syndrome (BBS)
NCT03287960	Phase 3	Completed	Jan 30, 2018	Sep 25, 2020	Leptin Receptor Deficiency Obesity
NCT02896192	Phase 3	Completed	Feb 14, 2017	May 25, 2020	Pro-opiomelanocortin (POMC) Deficiency Obesity
NCT02311673	Phase 2	Completed	Mar 19, 2015	Oct 26, 2016	Prader-Willi Syndrome
NCT02041195	Phase 1/2	Completed	Jan 1, 2014	Dec 1, 2014	Overweight and Obesity
NCT01749137	Phase 2	Completed	Jan 14, 2013	Sep 28, 2013	Overweight

Competing Products

7 competing products in Hypothalamic Obesity

See all competitors

Product	Company	Stage	Hype Score
Octreotide	Novartis	Approved	85
Mibavademab	Regeneron Pharmaceuticals	Phase 2	51
Part A: RM-718 or placebo (matched to specific RM-718 dose cohort) + Part B: RM-718 or placebo (matched to specific RM-718 dose cohort) + Part C: RM-718 + Part D: RM-718	Rhythm Pharmaceuticals	Phase 1/2	38
Setmelanotide + Placebo	Rhythm Pharmaceuticals	Phase 3	74
Setmelanotide	Rhythm Pharmaceuticals	Phase 2	49
Bivamelagon	Rhythm Pharmaceuticals	Phase 2	49
LB54640 + Placebo	Rhythm Pharmaceuticals	Phase 2	49

Other Products from Rhythm Pharmaceuticals

Setmelanotide + Moxifloxacin + Oral Placebo + SC PlaceboApproved

SetmelanotidePhase 3

Setmelanotide + PlaceboPhase 3